StockData

60 Degrees Pharmaceuticals vs Traws Pharma

SXTP and TRAW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SXTP and TRAW compare

Traws Pharma is the larger company, worth 2.1 times as much as 60 Degrees Pharmaceuticals ($3.9M against $1.8M).

60 Degrees Pharmaceuticals scores higher on the StockData Score (8 against 5 for Traws Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSXTPTRAW
Size and price
Market cap$1.8M$3.9M
Share price$0.518$0.251
Change, 1 year−89.5%−88.3%
Change, 5 years–−99.7%
Beta (5Y)2.091.19
Employees37
StockData Score
Total score8 (better)5
Valuation score3 (better)0
Growth score2 (better)1
Performance score1 (better)0
Health score24 (better)
Dividend score00
Valuation
P/S1.6×–
P/B0.7×–
FCF yield−488%–
Fair value$1.29–
Margin of safety59.7%–
Growth
Revenue growth (TTM)73.2%–
Revenue growth, 5Y average–64.6%
Profitability
Gross margin19.4%–
Operating margin−775%–
Net margin−730%–
FCF margin−801%–
Return on equity−322%–
Return on invested capital−659%–
Financial health
Debt / equity0.00–
Interest coverage−1134.8×–
Current ratio2.32 (better)0.93
Altman Z-score−22.23 (better)−85.39
Piotroski F-score24 (better)
Dividends and buybacks
Buyback yield–−109%
Shareholder yield0.00% (better)−109%
Ownership
Held by institutions21.5%40.1%
Held by insiders21.0%35.7%
Insider net buying, 12 months$30.1K$998K (better)
Short interest, % of float–6.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.